Ajanta Pharma Ltd. News and Updates

Name: Latest research reports of Ajanta Pharma Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Ajanta Pharma Ltd.
Rating: 5
Author: ICICI Securities Limited

Keep track of all breaking news on Ajanta Pharma Ltd. from all sources in a single place.

Load latest

Ajanta Pharma Ltd.

03 Feb 2021

2728.80

-1.64%

Ajanta Pharmaceuticals

Buy: Ajanta Pharma Ltd.

Target

ICICI Securities Limited

Q3 results were a beat on all fronts on the back of strong growth in branded generic sales in Emerging markets and India along with better gross margin performance. While the management expects subdued domestic growth in FY21 due to Covid-19, it expects high single digit growth for branded business in Asia, Africa (India, Asia, Africa- ~70% of sales) along with ~20% growth for US. On margins front, change in product mix (higher US revenues) notwithstanding, the management expects ~200-250 bps improvement in FY21, going ahead, with improving operating leverage and...

Number of FII/FPI investors increased from 346 to 373 in Dec 2024 qtr.

Ajanta Pharma Ltd.

02 Feb 2021

2728.80

-1.64%

Branded Generics drives earnings

Buy: Ajanta Pharma Ltd.

Target

Motilal Oswal

Ajanta Pharma (AJP) delivered higher than expected earnings, led by superior growth in the Branded Generics segment. This was further supported by a lower tax rate in 3QFY21. While the pace of ANDA filing has moderated in 9MFY21 due to COVID-related disruptions, it would improve with the easing of lockdown restrictions. We have raised our FY21E/FY22/FY23E estimates by 7.4%/7.1%/6.5% to factor in: a) recovery in DF/Asia/Africa, b) robust ANDA pipeline, and c) improved capacity utilization. We continue to value AJP at 23x 12 months...

Number of FII/FPI investors increased from 346 to 373 in Dec 2024 qtr.

Ajanta Pharma Ltd.

02 Feb 2021

2728.80

-1.64%

Ajanta Pharma (BUY): Another good quarter; resilient outlook to drive stock upside

Buy: Ajanta Pharma Ltd.

Target

BOB Capital Markets Ltd.

Ajanta Pharma (AJP) reported yet another excellent quarter with Q3 revenue/ EBITDA growth of 15%/30% YoY to Rs 7.5bn/Rs 2.4bn, surpassing our estimates by 11%/14%.

Ajanta Pharma Ltd. is trading above its 50 day SMA of 2665.9

Ajanta Pharma Ltd.

09 Nov 2020

2728.80

-1.64%

Buy Ajanta Pharma; target of Rs 1980: Anand Rathi

Moneycontrol

Anand Rathi is bullish on Ajanta Pharma has recommended buy rating on the stock with a target price of Rs 1980 in its research report dated November 05, 2020.

Ajanta Pharma Ltd. is trading above its 50 day SMA of 2665.9

Ajanta Pharma Ltd.

07 Nov 2020

2728.80

-1.64%

Accumulate Ajanta Pharma; target of Rs 1771: Dolat Capital Market

Moneycontrol

Dolat Capital Market recommended accumulate rating on Ajanta Pharma with a target price of Rs 1771 in its research report dated November 05, 2020.

Ajanta Pharma Ltd. is trading below its 100 day SMA of 2792.6

Buy Ajanta Pharmaceuticals; target of Rs 1960: ICICI Direct

Moneycontrol | 07 Nov 2020

Ajanta Pharma Ltd.

05 Nov 2020

2728.80

-1.64%

Ajanta Pharma

Accumulate: Ajanta Pharma Ltd.

Dolat Capital

Ajanta Pharma reported stellar Q2 beating our estimates on the operating performance. Top-line grew 8% YoY, in-line with our estimate, driven by US and branded Africa business. Other geographies including India were muted. However, lower opex aided margins at 38.3% (up 490 bps QoQ and 1,070 bps YoY), way higher than our estimates. While the same is expected to taper as activities resume in subsequent quarters,...